» Articles » PMID: 114638

Distribution of Gold in Blood Following Administration of Auranofin (SK&F D-39162)

Overview
Specialty Rheumatology
Date 1979 Jan 1
PMID 114638
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

After oral administration of auranofin (SK&F D-39162), a new antiarthritic gold compound, to rats, dogs and humans, a major portion (approximately 50%) of the blood gold content was found to be associated with cellular components. This property is in marked contrast to that reported for gold sodium thiomalate and represents another of the many physical, chemical and pharmacological differences between these therapeutic gold compounds. Although the clinical significance of this property is not presently known, it is recommended that pharmacokinetic studies involving auranofin include the assessment of both blood and serum gold levels.

Citing Articles

Gold nanoparticles: a revival in precious metal administration to patients.

Thakor A, Jokerst J, Zavaleta C, Massoud T, Gambhir S Nano Lett. 2011; 11(10):4029-36.

PMID: 21846107 PMC: 3195547. DOI: 10.1021/nl202559p.


Disease-modifying antirheumatic drugs. Potential effects in older patients.

Gardner G, Furst D Drugs Aging. 1995; 7(6):420-37.

PMID: 8601050 DOI: 10.2165/00002512-199507060-00003.


Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Tett S Clin Pharmacokinet. 1993; 25(5):392-407.

PMID: 7904547 DOI: 10.2165/00003088-199325050-00005.


Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells.

Dimartino M, Walz D Inflammation. 1980; 4(3):279-88.

PMID: 6776048 DOI: 10.1007/BF00915029.


Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Chaffman M, Brogden R, Heel R, Speight T, Avery G Drugs. 1984; 27(5):378-424.

PMID: 6426923 DOI: 10.2165/00003495-198427050-00002.